Rosetta and NYU form melanoma pact:
This article was originally published in Clinica
Rosetta Genomics has joined up with the NYU Medical Center to develop a diagnostic test for melanoma, using Rosetta's microRNA technology. The partnership will involve the use of Rosetta's diagnostic engine to screen more than 700 microRNAs in order to identify a diagnostic signature for the disease. The collaborators hope to identify microRNAs that can be used as prognostic indicators for the overall survival of melanoma patients, and to predict the risk that the cancer will metastasise. Rehovot, Israel-based Rosetta already has a pact with US-based NYU to develop a line of early detection products for lung and mesothelioma cancers. The firm also hopes to launch three novel tests during 2008, one for cancer of unknown primary (CUP) and two for lung cancer.